Our lead compound, GLIX1, is currently entering clinical development for glioblastoma through a joint venture with BioLineRx (Nasdaq:BLRX). At the proof of concept stage, is GLIX5, which is indicated in a much broader range of cancers. Further compounds are in the early stages of discovery.
